UK pharmacies report a surge in demand following the private market launch of Novo Nordisk's oral weight-loss pill, Wegovy. A National Pharmacy Association survey shows 70.6 per cent of pharmacies received enquiries for the semaglutide-based treatment. The 1.25mg starter dose costs roughly £100 a month, though the drug is currently unavailable via the NHS, creating a wealth-based gap in access.

Retailers face immediate financial headwinds as appetite suppressants reduce consumer food spending. UK supermarkets lost £780mn in sales in the year ending February due to GLP-1 drug users. This trend mirrors US data from Cornell University, where high-income households on these medications cut grocery spending by 8.2 per cent within six months.

Bramble Partners predicts UK calorie consumption will drop by 5 per cent by 2035. This shift threatens long-term revenue for food and beverage companies as systemic dietary changes become permanent. Investors should view the oral pill's ease of use as a catalyst for faster market penetration compared to the previous injectable version.